These recommendations come from early research showing the glycemic response to varied forms and amounts of CHO, before the advent of CGM to provide rate of change information and algorithms to modulate insulin doses.13–15 A recent review describes how the evidence base for these treatment amounts was supported by very limited quality evidence.16 There are little available data for hypoglycemia treatment amounts during the use of systems that proactively limit insulin delivery to avoid or lessen hypoglycemia. The gene discussed is INS; the disease is Hypoglycemia.